Market Research Reports

Biosimilars Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 - 2020

Description



The global market for biosimilars is getting a strong impetus due to the growing pressure to cut medical and healthcare expenses. Biosimilars are available at rates lower by 10%-30% in comparison to their parent products. The rising global geriatric population is fueling the frequency of chronic disorders, adding to the growth of the global biosimilars market.

The market study offers a comprehensive analysis of the global biosimilars industry, evaluating the essential factors such as growth drivers, restraints and challenges, and the development opportunities in this market.

Furthermore, the market forecasts, together with other detailed information, will assist existing as well as new participants in the global biosimilars market in assessing the potential of this market. Equipped with in-depth primary and secondary research, this market study on the global industry for biosimilars will help formulate market strategies that put the dominant market trends to good use.

Overview of the biosimilars market

The global market for biosimilar products is expecting a surge due to off-patent biologic products. Biosimilar drugs are cost-effective, which is a major factor responsible for the increased demand for these products. Further, the rising prevalence of various ailments is another factor boosting the growth of this market.

Coupled with government initiatives and assistance, the strategic collaborations between market players that lead to rising numbers of clinical trial activities for biosimilars and increased productivity are propelling the global biosimilars market significantly. However, the high production costs and intricacies of the product, together with several strict rules and regulations in various economies regarding the usage of the same, are adversely impacting the biosimilars industry. Adding to this is the innovative strategies devised by biologic drug producers, which are hampering new entrants into the global biosimilars market

Europe is the dominant regional market for biosimilars. The precise regulatory guidelines, presence of multiple biosimilar drugs such as tevagrastim, omnitrope, and binocrits, as well as the numerous products in the pipeline are the various reasons fueling the biosimilars market in Europe. The impending patent expiration of 15 biologics in the near future will also help the biosimilars market. On the other hand, the U.S. has a limited biosimilars industry, due to strict government regulations. The market in Asia Pacific is expected to register the fastest growth in the coming years.

Developing economies are significant potential markets for biosimilar products. But the global market is expected to face strong challenge from the complex infrastructure required for the production of biosimilars as well as the rigorous clinical trials needed to obtain the approval of regulatory bodies.

Companies mentioned in the research report

The global biosimilars industry is a highly fragmented market thanks to the large-scale activities of companies such as Abbott, Astra Zeneca, Ranbaxy Laboratories, Cipla, Sandoz, Bristol-Myers Squibb, and Genentech. Sandoz, the generics division of the Switzerland-based pharmaceutical giant Novartis, has recently launched Zarxio under the trade name Filgrastim-SNDZ in the U.S., marking the entry of biosimilars drugs in the nation. This move has also marked Sandoz as the leader in the global biosimilars market.

Major geographies analyzed under this research report are: 
  • Europe
  • North America 
  • Asia-Pacific 
  • Rest of the World 
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements 
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents


TABLE OF CONTENTS

1) INTRODUCTION
 1.1 Objective of the Research
 1.2 Report Highlights
 1.3 Scope of the Report
 1.4 Research Methodology

2) MARKET OUTLINE
2.1. Defining the global biosimilar market
2.2. Driving factor analysis
2.2.1. Demand and Supply-side drivers
2.2.2. Restraints & opportunities
2.2.3. Key points
2.3. Issues related with biosimilar
2.4. Potential matrix for global biosimilar 
2.4.1. Products
2.4.2. Applications
2.5. Biosimilar market dynamics
2.6. Pricing of biosimilar drug
2.7. Biosimilar products geographical trend

3) BIOSIMILAR PRODUCTS MARKET
3.1. Recombinant glycosylated proteins
3.1.1. Drivers & restraints
3.1.2. Erythropoietin (EPO)
3.1.3. Urokinase
3.1.4. Glucocerebrosidase
3.1.5. Monoclonal antibodies
3.1.5.1. Chimaeric antibodies
3.1.5.2. Humanized / cdr-grafted / reshaped antibodies
3.1.5.3. Human antibodies and fusion protein
3.1.6. Follitropin
3.1.7. Thyrotropin
3.1.8. Becaplermin
3.1.9. Granulocyte-macrophage-CSF (GM-CSF)
3.1.10. Recombinant Human DNASE (RHDNASE)
3.1.11. Factor VIIA
3.1.11.1. Factor VIII
3.1.11.2. Factor IX
3.1.12. Activated protein-c
3.1.13. Tissue plasminogen activator
3.2. Recombinant non-glycosylated protein
3.2.1. Drivers and restraints
3.2.2. Insulin
3.2.2.1. Drivers & restraints
3.2.2.2. Opportunities
3.2.3. Interferons
3.2.3.1. Interferon alfa
3.2.3.2. Interferon beta-1a
3.2.3.3. Interferon gamma
3.2.4. Recombinant human growth hormone
3.2.5. Lepirudin
3.2.6. Interleukin-11
3.2.7. Anakinra
3.2.8. Interleukin – 2 (Il-2)
3.2.9. Granulocyte colony-stimulating factor (G-CSF)
3.3. Peptides
3.3.1. Drivers
3.3.2. Restraints & opportunities
3.3.3. Cyclosporine
3.3.4. Calcitonin
3.3.5. Bivalirudin
3.3.6. Enfuvirtide
3.3.7. Glucagon
3.3.8. Eptifibatide
3.3.9. Octreotide
3.3.10. Desmopressin
3.3.11. LH-RH (Leuprolide)
3.3.12. Nesiritide
3.3.13. Teriparatide

4) BIOSIMILAR TECHNOLOGY
4.1. Recombinant DNA technology (RDNA technology)
4.1.1. Drivers
4.1.2. Restraints & opportunities
4.2. Chromatography
4.2.1. Drivers & opportunities
4.2.2. Top player analysis
4.2.3. Liquid chromatography (LC)
4.2.4. Gas chromatography (GC)
4.3. Bioassay
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Techniques in bioassay
4.3.3.1. Six point assay
4.3.3.2. Multiple point assays
4.3.3.3. Interpolation method
4.3.3.4. Bracketing method
4.3.3.5. Matching bioassays
4.4. Monoclonal antibodies (MAB) technology
4.4.1. Drivers
4.4.2. Restraints & opportunities
4.4.3. Top player analysis
4.5. Western blotting
4.5.1. Drivers
4.5.2. Restraints & opportunities
4.6. Protein sequencing
4.6.1. Drivers
4.6.2. Restraints & opportunities
4.7. Nuclear magnetic resonance (NMR) technology
4.7.1. Drivers
4.7.2. Restraints & opportunities
4.8. Electrophoresis
4.8.1. Drivers
4.8.2. Restraints & opportunities
4.8.3. GEL electrophoresis
4.8.4. Capillary electrophoresis
4.9. Mass spectrometry
4.9.1. Drivers
4.9.2. Restraints

5) BIOSIMILAR APPLICATION MARKET
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.2. Oncology
5.2.1. Drivers
5.2.2. Restraints & opportunities
5.2.3. Lung cancer
5.2.4. Colorectal cancer
5.2.5. Breast cancer
5.2.6. Cervical cancer
5.2.7. Leukemia
5.2.7.1. Drivers
5.2.8. Prostate cancer
5.3. Infectious diseases
5.3.1. HIV/Aids
5.3.1.1. Drivers
5.3.2. Hepatitis B
5.3.3. Hepatitis C
5.4. Chronic and autoimmune diseases
5.4.1. Diabetes
5.4.1.1. Drivers
5.4.2. Neutropenia
5.4.3. Multiple sclerosis
5.4.3.1. Drivers
5.4.3.2. Inhibitors and opportunities
5.4.4. Cystic fibrosis
5.4.5. Rheumatoid arthritis (RA)
5.4.5.1. Drivers
5.4.5.2. Restraints
5.4.6. Acromegaly
5.4.6.1. Driver
5.4.7. Leprosy
5.5. Hematology
5.5.1. Drivers
5.5.2. Chemotherapy induced anemia
5.5.2.1. Drivers
5.5.2.2. Restraints and opportunities
5.5.3. Hemophilia
5.5.4. Pulmonary embolism
5.5.4.1. Drivers
5.6. Growth hormone deficiency (GHD)
5.6.1. Drivers
5.7. Other diseases
5.7.1. Gaucher disease
5.7.2. Osteoporosis
5.7.3. Fertility disorders (Infertility)
5.7.4. Skin ulcer
5.7.5. Hypoglycemia
5.7.6. Nocturnal enuresis
5.7.7. Congestive heart failure (CHF)
5.7.8. Systemic sepsis
5.7.9. Others

6) BIOSIMILAR SERVICE MARKET
6.1. Clinical trials
6.1.1. Drivers & restraints
6.1.2. Phase I
6.1.3. Phase II
6.1.4. Phase III
6.2. Contract research and manufacturing services
6.2.1. Drivers
6.2.2. Restraints & opportunities

7) GEOGRAPHIC ANALYSIS
7.1. North America biosimilar market
7.2. EMEA biosimilar market
7.3. Asia-Pacific biosimilar market
7.4. Latin America Biosimilars market

8) COMPANY PROFILES
8.1.1. Teva
8.1.2. Sandoz
8.1.3. Hospira
8.1.4. Mylan
8.1.5. Actavis
8.1.6. Biocon Ltd.
8.1.7. Cipla Ltd.
8.1.8. Dr. Reddy's Laboratories Ltd.
8.1.9. Wockhardt Ltd
8.1.10. Stada Arzneimittel AG

Pre Book Price: $4315.5 Original Price: $4795
Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research